RT Journal Article
SR Electronic
T1 Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.12.22269148
DO 10.1101/2022.01.12.22269148
A1 Davies, Mary-Ann
A1 Kassanjee, Reshma
A1 Rosseau, Petro
A1 Morden, Erna
A1 Johnson, Leigh
A1 Solomon, Wesley
A1 Hsiao, Nei-Yuan
A1 Hussey, Hannah
A1 Meintjes, Graeme
A1 Paleker, Masudah
A1 Jacobs, Theuns
A1 Raubenheimer, Peter
A1 Heekes, Alexa
A1 Dane, Pierre
A1 Bam, Jamy-Lee
A1 Smith, Mariette
A1 Preiser, Wolfgang
A1 Pienaar, David
A1 Mendelson, Marc
A1 Naude, Jonathan
A1 Schrueder, Neshaad
A1 Mnguni, Ayanda
A1 Le Roux, Sue
A1 Murie, Katie
A1 Prozesky, Hans
A1 Mahomed, Hassan
A1 Rossouw, Liezel
A1 Wasserman, Sean
A1 Maughan, Deborah
A1 Boloko, Linda
A1 Smith, Barry
A1 Taljaard, Jantjie
A1 Symons, Greg
A1 Ntusi, Ntobeko
A1 Parker, Arifa
A1 Wolter, Nicole
A1 Jassat, Waasila
A1 Cohen, Cheryl
A1 Lessells, Richard
A1 Wilkinson, Robert J
A1 Arendse, Juanita
A1 Kariem, Saadiq
A1 Moodley, Melvin
A1 Vallabhjee, Krish
A1 Wolmarans, Milani
A1 Cloete, Keith
A1 Boulle, Andrew
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/01/12/2022.01.12.22269148.abstract
AB Objectives We aimed to compare COVID-19 outcomes in the Omicron-driven fourth wave with prior waves in the Western Cape, the contribution of undiagnosed prior infection to differences in outcomes in a context of high seroprevalence due to prior infection, and whether protection against severe disease conferred by prior infection and/or vaccination was maintained.Methods In this cohort study, we included public sector patients aged ≥20 years with a laboratory confirmed COVID-19 diagnosis between 14 November-11 December 2021 (wave four) and equivalent prior wave periods. We compared the risk between waves of the following outcomes using Cox regression: death, severe hospitalization or death and any hospitalization or death (all ≤14 days after diagnosis) adjusted for age, sex, comorbidities, geography, vaccination and prior infection.Results We included 5,144 patients from wave four and 11,609 from prior waves. Risk of all outcomes was lower in wave four compared to the Delta-driven wave three (adjusted Hazard Ratio (aHR) [95% confidence interval (CI)] for death 0.27 [0.19; 0.38]. Risk reduction was lower when adjusting for vaccination and prior diagnosed infection (aHR:0.41, 95% CI: 0.29; 0.59) and reduced further when accounting for unascertained prior infections (aHR: 0.72). Vaccine protection was maintained in wave four (aHR for outcome of death: 0.24; 95% CI: 0.10; 0.58).Conclusions In the Omicron-driven wave, severe COVID-19 outcomes were reduced mostly due to protection conferred by prior infection and/or vaccination, but intrinsically reduced virulence may account for an approximately 25% reduced risk of severe hospitalization or death compared to Delta.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding for the Western Cape Provincial Health Data Centre from the Western Cape Department of Health, the US National Institutes for Health (R01 HD080465, U01 AI069924), the Bill and Melinda Gates Foundation (1164272, 119327), the United States Agency for International Development (72067418CA00023), the European Union (101045989), the Wellcome Trust (203135/Z/16/Z, 222574) and the Medical Research Council of South Africa. RJW receives support from the Francis Crick Institute which is funded by Wellcome (FC0010218), MRC (UK) (FC0010218) and Cancer Research UK (FC0010218). He also receives support from Wellcome (203135, 222574) and the Medical Research Council of South Africa.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Research Ethics Committee, University of Cape Town Faculty of Health Sciences, South AfricaI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.